CA3140053A1 - Controlling intersample analyte variability in complex biological matrices - Google Patents

Controlling intersample analyte variability in complex biological matrices Download PDF

Info

Publication number
CA3140053A1
CA3140053A1 CA3140053A CA3140053A CA3140053A1 CA 3140053 A1 CA3140053 A1 CA 3140053A1 CA 3140053 A CA3140053 A CA 3140053A CA 3140053 A CA3140053 A CA 3140053A CA 3140053 A1 CA3140053 A1 CA 3140053A1
Authority
CA
Canada
Prior art keywords
dilution
analyte
model
dilution series
series
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140053A
Other languages
English (en)
French (fr)
Inventor
Thomas HRAHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Operating Co Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of CA3140053A1 publication Critical patent/CA3140053A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3140053A 2019-05-17 2020-05-15 Controlling intersample analyte variability in complex biological matrices Pending CA3140053A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849212P 2019-05-17 2019-05-17
US62/849,212 2019-05-17
PCT/US2020/033033 WO2020236544A1 (en) 2019-05-17 2020-05-15 Controlling intersample analyte variability in complex biological matrices

Publications (1)

Publication Number Publication Date
CA3140053A1 true CA3140053A1 (en) 2020-11-26

Family

ID=71016636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140053A Pending CA3140053A1 (en) 2019-05-17 2020-05-15 Controlling intersample analyte variability in complex biological matrices

Country Status (11)

Country Link
US (1) US12480956B2 (enExample)
EP (1) EP3969900A1 (enExample)
JP (1) JP7748877B2 (enExample)
KR (1) KR20220009948A (enExample)
CN (1) CN113826170B (enExample)
AU (1) AU2020278570A1 (enExample)
BR (1) BR112021022532A8 (enExample)
CA (1) CA3140053A1 (enExample)
IL (1) IL288014A (enExample)
SG (1) SG11202111365QA (enExample)
WO (1) WO2020236544A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220386905A1 (en) * 2021-03-02 2022-12-08 Pacific Diabetes Technologies Inc Signal processing algorithm for improving accuracy of a continuous glucose sensor and a combined continuous glucose sensor and insulin delivery cannula
GB202116626D0 (en) * 2021-11-18 2022-01-05 Fluidic Analytics Ltd Improvements in or relating to a method of analysing a component in a sample
CN117497037B (zh) * 2023-11-17 2024-08-16 上海倍谙基生物科技有限公司 一种基于广义线性模型的培养基组分敏感性分析方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69128350T2 (de) 1990-06-11 1998-03-26 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5945527A (en) 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
ES2371539T3 (es) * 2002-04-23 2012-01-04 Home Access Health Corporation Análisis cuantitativo de una muestra biológica de cantidad desconocida.
US7373256B2 (en) 2005-04-19 2008-05-13 Nicholson Jeremy K Method for the identification of molecules and biomarkers using chemical, biochemical and biological data
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
MX2010000578A (es) 2007-07-17 2010-04-30 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
US8260556B2 (en) 2008-08-21 2012-09-04 Bio-Rad Laboratories, Inc. Calibration surface method for determination on of analyte ratios
US9551703B2 (en) * 2009-08-04 2017-01-24 The Johns Hopkins University High precision quantitative assay composition and methods of use therefor
AU2011240677B2 (en) 2010-04-12 2015-05-14 Somalogic Operating Co., Inc. 5-position modified pyrimidines and their use
JP2013528379A (ja) 2010-05-21 2013-07-11 オームクス コーポレーション Ｐｓａ酵素活性アッセイによる癌の検出
CA2825196C (en) * 2011-01-21 2021-01-05 Theranos, Inc. Systems and methods for sample use maximization
EP3425090B1 (en) * 2014-02-18 2019-10-23 SomaLogic, Inc. Compositions and methods for detecting microorganisms
AU2016243656A1 (en) 2015-03-30 2017-11-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing

Also Published As

Publication number Publication date
SG11202111365QA (en) 2021-11-29
US20220260585A1 (en) 2022-08-18
BR112021022532A2 (enExample) 2021-12-28
BR112021022532A8 (pt) 2022-10-11
JP2022532212A (ja) 2022-07-13
CN113826170A (zh) 2021-12-21
CN113826170B (zh) 2024-12-27
US12480956B2 (en) 2025-11-25
IL288014A (en) 2022-01-01
AU2020278570A1 (en) 2022-01-06
JP7748877B2 (ja) 2025-10-03
EP3969900A1 (en) 2022-03-23
KR20220009948A (ko) 2022-01-25
WO2020236544A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
EP3660512B1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
WO2017139254A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
US12480956B2 (en) Controlling intersample analyte variability in complex biological matrices
US20230071234A1 (en) Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
WO2016123058A1 (en) Biomarkers for detection of tuberculosis risk
WO2015153860A1 (en) Glomerular filtration rate biomarkers and uses thereof
US20180356419A1 (en) Biomarkers for detection of tuberculosis risk
HK40061957A (en) Controlling intersample analyte variability in complex biological matrices
US20250180571A1 (en) Methods for Sample Quality Assessment
US20250052766A1 (en) Methods for Sample Quality Assessment
US20250231198A1 (en) Methods for Sample Quality Assessment
US20250208119A1 (en) Methods for Sample Quality Assessment
KR20240137560A (ko) 샘플 품질 평가 방법
JP2025186325A (ja) 耐糖能異常障害を決定する方法
CA3254647A1 (en) METHODS FOR EVALUATING THE QUALITY OF A SAMPLE
JP2025534223A (ja) タバコ使用状態を査定する方法
HK40026777B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1220251B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220512

EEER Examination request

Effective date: 20220512

EEER Examination request

Effective date: 20220512

EEER Examination request

Effective date: 20220512

EEER Examination request

Effective date: 20220512